Endocrinology Advisor
banner
endocrinologyadv.bsky.social
Endocrinology Advisor
@endocrinologyadv.bsky.social
Endocrinology Advisor provides healthcare professionals with comprehensive information and clinical news on the management of endocrine conditions.
Still catching up on research from #ENDO2025? Find all of Endocrinology Advisor's coverage from this month's conference below ⬇️ @endocrinesociety.bsky.social
Endocrine Society Archives
Presenting research from ENDO, the annual meeting of the Endocrine Society.
www.endocrinologyadvisor.com
July 24, 2025 at 1:49 PM
Relative to #GLP1RA and #DPP4i use, #SGLT2i use was associated with an increased risk for #erythrocytosis but not an increased risk for #thrombosis in #T2D.
SGLT2 Inhibitor Use Linked to Increased Risk for Erythrocytosis, Not Thrombosis
SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not thrombosis among patients with type 2 diabetes.
www.endocrinologyadvisor.com
July 23, 2025 at 5:04 PM
Pre-visit patient activation enhanced the positive effect of PCP academic detailing on diabetes #deprescribing rates among older adults with #T2D.

@kaiser-permanente.bsky.social @yaleschoolofmed.bsky.social
Academic Detailing Plus Pre-Visit Handout Improves Diabetes Deprescribing
Academic detailing plus pre-visit patient activation was associated with sustained diabetes deprescribing rates at 12 months in older adults with T2D.
www.endocrinologyadvisor.com
July 22, 2025 at 5:07 PM
Reduced heavy menstrual bleeding was sustained with #linzagolix therapy, regardless of adjunct hormonal add-back therapy, at 1 year among patients with #UterineFibroids.

@yaleschoolofmed.bsky.social @ox.ac.uk @goetheuni.bsky.social @ub.edu
Linzagolix Sustains Reduced Menstrual Bleeding in Uterine Fibroids at 1 Year
Linzagolix therapy was associated with significantly reduced heavy menstrual bleeding by week 52 among patients with uterine fibroids.
www.endocrinologyadvisor.com
July 22, 2025 at 2:19 PM
From #ENDO2025: There are significant reductions in patient-reported symptom severity among patients with #acromegaly treated with paltusotine.

@endocrinesociety.bsky.social
Paltusotine Improves Patient-Reported Acromegaly Symptoms
Paltusotine treatment is associated with significant reductions in patient-reported symptom severity among patients with acromegaly.
www.endocrinologyadvisor.com
July 17, 2025 at 7:43 PM
From #ENDO2025: Among #tirzepatide users, women experienced greater reductions in total #cholesterol, LDL cholesterol, and weight than men.

@endocrinesociety.bsky.social @mayoclinic.org
Tirzepatide Cardiometabolic Benefits Greater in Women vs Men
Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.
www.endocrinologyadvisor.com
July 17, 2025 at 3:37 PM
From #ENDO2025: #ThyroidCancer attributable to high #BMI increased from 1990 to 2021, especially among older adults and men.

@endocrinesociety.bsky.social
Thyroid Cancer Burden Due to High BMI on the Rise in US
Thyroid cancer burden attributable to high BMI was increasing between 1990 and 2021 in the US, especially among men and older adults.
www.endocrinologyadvisor.com
July 16, 2025 at 5:10 PM
From #ENDO2025: Presence of #adrenal #adenoma was associated with lower #WeightLoss among patients with #obesity using #GLP1 or GIP/GLP-1 receptor agonists.

@endocrinesociety.bsky.social
Adrenal Adenomas May Attenuate Weight Loss With Incretin-Based Therapy
Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP-1 RAs.
www.endocrinologyadvisor.com
July 16, 2025 at 2:51 PM
From #ENDO2025: In pediatric #CongenitalAdrenalHyperplasia, crinecerfont is associated with sustained reductions in androstenedione levels and #glucocorticoid doses at 1 year.

@endocrinesociety.bsky.social
Crinecerfont Maintains A4, GC Reductions in Pediatric CAH at 1 Year
Crinecerfont is associated with sustained reductions in androstenedione and GC doses at 1 year in congenital adrenal hyperplasia.
www.endocrinologyadvisor.com
July 15, 2025 at 7:22 PM
From #ENDO2025: Women with #thrombotic disease and comorbid #PCOS had higher rates of #vascular events and presented at a younger age than those with thrombotic disease and no PCOS.

@endocrinesociety.bsky.social
PCOS May Increase Vascular Event Risk in Thrombotic Disease
PCOS was associated with an increased risk for vascular events including stroke among women with thrombotic disease, and a lower mean age.
www.endocrinologyadvisor.com
July 15, 2025 at 5:12 PM
From #ENDO2025: Although the addition of #metformin offered little benefit, combined #OralContraceptive pills were associated with improved #obesity outcomes in hyperandrogenic #PCOS.

@endocrinesociety.bsky.social @upenn.edu
COCPs Improve Obesity Outcomes in Hyperandrogenic PCOS
COCPs were associated with improved obesity outcomes among patients with hyperandrogenic PCOS, but metformin added little benefit.
www.endocrinologyadvisor.com
July 15, 2025 at 2:56 PM
From #ENDO2025: #Osteoporosis treatment following fragility #Fracture was associated with significantly reduced #hospitalization and mortality risks among patients aged 80 years and older.

@endocrinesociety.bsky.social @clevelandclinic.bsky.social @upstatemedical.bsky.social
Osteoporosis Treatment After Fragility Fracture Lowers Mortality Risk
Osteoporosis treatment was associated with reduced hospitalization and mortality risks following fragility fracture after 80 years of age.
www.endocrinologyadvisor.com
July 14, 2025 at 7:54 PM
Quiz Time! Test your knowledge on #nutritional support strategies in #GLP1 use. #EndoSky
Test Your Knowledge on Nutritional Support Strategies in GLP-1 Drug Use
Which of the statements about nutritional support strategies for patients using GLP-1 drugs are correct?
www.endocrinologyadvisor.com
July 11, 2025 at 2:55 PM